An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19.
Fu W, Liu Y, Liu L, Hu H, Cheng X, Liu P, Song Z, Zha L, Bai S, Xu T, Yuan S, Lu F, Shang Z, Zhao Y, Wang J, Zhao J, Ding L, Chen J, Zhang L, Zhu T, Zhang X, Lu H, Xu J.
Fu W, et al. Among authors: zhang l, zhang x.
EClinicalMedicine. 2020 Oct;27:100547. doi: 10.1016/j.eclinm.2020.100547. Epub 2020 Sep 20.
EClinicalMedicine. 2020.
PMID: 32984784
Free PMC article.